Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M120,478Revenue $M13,999Net Margin (%)30.3Z-Score16.9
Enterprise Value $M118,169EPS $1.6Operating Margin %38.1F-Score8
P/E(ttm))27.1Cash Flow Per Share $0Pre-tax Margin (%)39.0Higher ROA y-yY
Price/Book18.410-y EBITDA Growth Rate %19.2Quick Ratio1.0Cash flow > EarningsY
Price/Sales8.25-y EBITDA Growth Rate %22.3Current Ratio1.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %6.1ROA % (ttm)38.6Higher Current Ratio y-yN
Dividend Yield %1.4Insider Buy (3m)0ROE % (ttm)68.5Less Shares Outstanding y-yY
Payout Ratio %33.0Shares Outstanding M2,750ROI % (ttm)69.1Gross Margin Increase y-yY

Gurus Latest Trades with NVO

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVORuane Cunniff 2014-09-30 Reduce-0.02%$43.9 - $49.03
($46)
$ 43.81-5%Reduce -52.87%75,642
NVORuane Cunniff 2014-06-30 Reduce-0.02%$42.28 - $46.52
($44.12)
$ 43.81-1%Reduce -33.85%160,492
NVORuane Cunniff 2014-03-31 Reduce-0.01%$36.722 - $48.23
($42.37)
$ 43.813%Reduce -21.98%242,630
NVORuane Cunniff 2013-12-31 Add0.02%$32.72 - $36.886
($34.84)
$ 43.8126%Add 58.71%62,194
NVORuane Cunniff 2013-06-30 Buy 0.04%$30.11 - $35.33
($33.29)
$ 43.8132%New holding, 34640 sh.34,640
NVOMario Gabelli 2013-03-31 Reduce$32.24 - $38.86
($34.93)
$ 43.8125%Reduce -60.32%1,734
NVOJohn Hussman 2012-09-30 Sold Out -0.01%$28.83 - $32.15
($30.65)
$ 43.8143%Sold Out0
NVOKen Fisher 2012-06-30 Add1.01%$25.98 - $30.38
($28.44)
$ 43.8154%Add 519.97%2,786,828
NVOJohn Hussman 2012-03-31 Reduce$23.09 - $28.94
($24.82)
$ 43.8176%Reduce -40%3,000
NVOMario Gabelli 2011-12-31 Add$18.92 - $23.05
($21.5)
$ 43.81104%Add 66.87%5,590
NVOJohn Hussman 2011-09-30 Buy 0.01%$19.46 - $25.45
($22.27)
$ 43.8197%New holding, 5000 sh.5,000
NVOKen Fisher 2011-06-30 Add0.06%$23.4 - $26.29
($24.91)
$ 43.8176%Add 68.56%456,434
NVOMario Gabelli 2011-06-30 Reduce$23.4 - $26.29
($24.91)
$ 43.8176%Reduce -21.18%3,350
NVOJohn Keeley 2011-06-30 Sold Out -0.01%$23.4 - $26.29
($24.91)
$ 43.8176%Sold Out0
NVOKen Fisher 2011-03-31 Buy 0.09%$22.16 - $25.59
($23.8)
$ 43.8184%New holding, 270785 sh.270,785
NVOJohn Keeley 2010-12-31 Buy 0.01%$18.2 - $22.43
($20.77)
$ 43.81111%New holding, 2780 sh.2,780
NVOMario Gabelli 2010-09-30 Reduce$16.23 - $19.85
($17.64)
$ 43.81148%Reduce -28.77%4,420
NVOVanguard Health Care Fund 2010-09-30 Sold Out -0.19%$16.23 - $19.85
($17.64)
$ 43.81148%Sold Out0
NVOMario Gabelli 2010-06-30 Reduce$14.8 - $17.06
($15.97)
$ 43.81174%Reduce -56.26%6,205
NVOVanguard Health Care Fund 2010-06-30 Reduce-0.08%$14.8 - $17.06
($15.97)
$ 43.81174%Reduce -42.86%400,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVO is held by these Gurus:


News about NVO:

Articles On GuruFocus.com
Examining The Three Largest Guru Portfolios Oct 24 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Sep 02 2014 
Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Aug 23 2014 
GAMCO CIO Howard Ward on Reliable Consumer Stock Ideas Apr 09 2014 
Assessing the New Boss at National Oilwell Varco Mar 31 2014 
Amgen Inc: As Good as It Gets? Feb 20 2014 
Shire PLC: Time to Panic? Feb 07 2014 

More From Other Websites
Business Highlights Dec 19 2014
NovoEight®, phase 3 data show reduction in annualised bleeding rate over time in people with... Dec 10 2014
Share repurchase programme Dec 10 2014
How To Profit From The Obesity Epidemic Dec 08 2014
Paralegal: Sanofi fired her for whistleblowing Dec 05 2014
Paralegal: Sanofi fired her for whistleblowing Dec 05 2014
A Look At 4 ETFs From The 4 'Least Corrupt' Countries Dec 04 2014
Australian Diabetes Management Market and Diabetes Diagnostic Devices Market Spurted by $46 Million... Dec 01 2014
Share repurchase programme Dec 01 2014
[$$] Novo Could Put Money Where Its Mouth Is Nov 26 2014
Novo Nordisk's Victoza Recommended for Label Expansion Nov 24 2014
Changes in Novo Nordisk's Executive Management Nov 24 2014
Share repurchase programme Nov 24 2014
Sanofi Shakes Off Patent Losses Nov 24 2014
Victoza® receives positive CHMP opinion for use in adults with type 2 diabetes and moderate renal... Nov 21 2014
Sanofi's Bullish Pipeline Forecast Underwhelms Street Nov 20 2014
Share repurchase programme Nov 17 2014
Novo Nordisk second best in the world at providing access to medicine Nov 17 2014
Media Release - Top 100 Employer Nov 04 2014
New phase 3a data demonstrate that 9 out of 10 adults with obesity lost weight with liraglutide 3 mg... Nov 04 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

Gintaras58
ReplyGintaras58 - 9 months ago
few excellent prducts to come soon
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK